Michele Bellon

Translating excellence in research into benefits for public health. Institut Pasteur of Shanghai (IPS) is an independent, non-profit life sciences institute to address public health issues in China and the Asian region. IPS creates synergies between Institut Pasteur and the Chinese Academy of Sciences networks, leveraging all the assets of Shanghai as one of Asia’s leading business and technology hubs. Our scientists are engaged in a broad range of infectious diseases research programs ranging from viral hepatitis, HIV, respiratory infections, to virus-induced cancers. IPS is in an ideal strategic position to conduct research and development in life sciences in China. Together with its academic and industry partners, IPS’s goal is to develop product candidates in the field of diagnostics, vaccines and therapeutics.

The RATP Group is the world's fifth largest public transport company, carrying 12 million people every day in France and around the world. It boasts unrivalled experience in design, project management, operation and maintenance of all types of urban and suburban transport, making it an industry leader called upon around the globe for its expertise. The RATP Group already operates in 12 countries through 50 subsidiaries and is stepping up its international expansion through some major projects worldwide. The RATP Group is also a strong proponent of sustainable mobility. It has the know-how to meet new service quality challenges by anticipating new passenger expectations in terms of information, accessibility, safety, regularity and service innovation. The RATP Group at a glance: - 56,000 people in France and abroad - 4 billion journeys a year in Ile-de-France - Operations in 12 countries Specialisations: Operation, maintenance and engineering of passenger transport networks: urban and suburban transport (train, metro, tramway, bus)

Translating excellence in research into benefits for public health. Institut Pasteur of Shanghai (IPS) is an independent, non-profit life sciences institute to address public health issues in China and the Asian region. IPS creates synergies between Institut Pasteur and the Chinese Academy of Sciences networks, leveraging all the assets of Shanghai as one of Asia’s leading business and technology hubs. Our scientists are engaged in a broad range of infectious diseases research programs ranging from viral hepatitis, HIV, respiratory infections, to virus-induced cancers. IPS is in an ideal strategic position to conduct research and development in life sciences in China. Together with its academic and industry partners, IPS’s goal is to develop product candidates in the field of diagnostics, vaccines and therapeutics.